LOS ANGELES--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced the appointment of seasoned biopharmaceutical industry executive James G. McArthur, Ph.D. to the Company’s Board of Directors. Dr. McArthur brings more than 25 years of experience in drug development, financial, strategic and operational experience. Dr. McArthur has successfully founded five biotech companies and brings extensive knowledge of the healthcare space, having led companies through all phases of development from technology assessment through lead identification and proof of concept human studies.
“James’ extensive knowledge of and experience with all aspects of drug development as well as his broad healthcare industry connections will be vital as we advance the clinical development of our TCR product candidates for the treatment of tumors expressing KK-LC-1 in collaboration with the National Cancer Institute,” stated Gang Zeng, Ph.D., Chief Executive Officer of T-Cure. “Dr. McArthur has previously established multiple successful biotechnology companies, led the R&D efforts to build out portfolios from the ground up, and found validating partnership opportunities with big pharma. This experience will be essential as T-Cure progresses its pipeline and increases its focus on product development efforts moving forward.”
Dr. McArthur is a founder, a member of the Board of Directors and formerly served as CEO of Imara, Inc., a public clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. He was also a founder of Vtesse, a company developing drugs for patients suffering from Niemann-Pick Type C1 Disease, which was subsequently acquired by Sucampo Pharmaceuticals, and most recently founded Tiburio, a clinical stage company focused on rare neuroendocrine disorders. Prior to co-founding Imara, Vtesse and Cydan, Dr. McArthur was an entrepreneur-in-residence at HealthCare Ventures. There, he helped to create and then served as Chief Scientific Officer of Synovex Co., a rheumatoid arthritis therapeutic company which was subsequently acquired by Roche. He has extensive research and development expertise in a number of areas including rare diseases, oncology, hematologic diseases, vascular diseases as well as gene therapy. Dr. McArthur is a listed investor on 15 issued patents and multiple patent applications. He previously served as a member of the Board of Directors of Nightstar Therapeutics, a clinical stage gene therapy company which was acquired by Biogen. Dr. McArthur obtained a PhD in biochemistry and oncology at McGill University and was a post-doctoral fellow studying Immunology at Massachusetts Institute of Technology and the University of California at Berkeley with Noble laureate James Allison.
About T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on isolating high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 and other antigens associated with solid tumors with significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma.
More information is available at www.T-Cure.com.
Forward Looking Statements
T-Cure cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may”, “might”, “will”, “should”, “could”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “intend”, “future”, “potential” or “continue”, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.